Publisher’s Spotlight: Citeline News And Insights App

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

Scrip Mobile App
• Source: Shutterstock

Enjoy a faster, streamlined experience, tailor-made for your mobile device – now available on the App Store and Google Play.

Effortlessly switch between publications, customize your home screen, and search for articles across the full suite of Citeline publications. Stay up to date with breaking news notifications and save offline articles for later with the personalized 'my content' feature, ensuring you never miss a beat.

This is the new way to experience your news and insights.

  • Seamless Experience: The mobile-native app provides streamlined access to all Citeline’s news and insights publications.
  • Swipe and Customize: Effortlessly switch between publications and customize your experience, ensuring you only see what matters most.
  • Detailed Search: Discover the latest insights at your fingertips, searching the latest articles across multiple publications.
  • Anytime, Anywhere: Bookmark articles for later, even offline! Access your saved articles in "My Content" for reading anytime, anywhere.
  • Endless Connectivity: Enjoy a hassle-free experience – once logged in, stay connected even when switching to the browser version of the publication.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

Optimizing Drug Pipelines With Biophysical Methods

Optimizing Drug Pipelines With Biophysical Methods”, your view into how using biophysical techniques can enhance and streamline processes throughout the drug discovery and validation cycle.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

GSK Looks To Catch Up In mRNA Vaccines With New CureVac Deal

 

GSK will assume full control of mRNA shots in infectious disease, allowing CureVac to cut costs and pivot its research to oncology.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains